Laurus Labs invests over Rs 99 crore in subsidiary

19 Feb 2024 Evaluate

Laurus Labs has infused further equity into its wholly-owned subsidiary Laurus Synthesis (LSPL) via subscribing to the rights issue offered by LSPL for a cash consideration of Rs 99,13,12,308 for acquisition of 7,600 Equity shares of Rs 10 each at a premium of Rs 1,30,425.83 per share.

The Company has infused further equity via rights issue keeping in view of the funds requirements of LSPL. The Company has paid the share application money and 7600 Equity shares of Rs 10 each were allotted.

Laurus Labs is a leading research and development driven pharmaceutical company in India. The company has grown consistently to become one of the leading manufacturers of APIs for anti-retroviral (ARV) and Hepatitis C. It also manufactures APIs in oncology and other therapeutic areas.


Laurus Labs Share Price

570.80 3.65 (0.64%)
26-Dec-2024 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1841.50
Dr. Reddys Lab 1355.15
Cipla 1489.20
Lupin 2181.60
Zydus Lifesciences 959.55
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.